Streetinsider.com's Hot Lunchtime Reads 5/26: (MNST) (TASR) (AEGR) (MSFT) May 26, 2015 12:09PM
Juxtapid Phase 3 Achieves in HoFH; Needham & Company Maintains Aegerion (AEGR) at 'Hold' Pending Better Visibility May 26, 2015 11:48AM
Needham & Company Downgrades Aegerion Pharmaceuticals (AEGR) to Hold Oct 31, 2014 08:01AM
Aegerion Pharmaceuticals (AEGR) Run Up Not Over; PT Doubled at Needham & Company Jul 22, 2013 07:30AM
StreetInsider.com Pre-Open Movers 12/24: (HLF) (NUS) (FB) Higher; (ALXA) (HOV) (AEGR) Lower (more...) Dec 24, 2012 09:31AM


Dec 21, 2012 11:18AM Notable Analyst Rating Changes 12/21: (ACMP) (CIB) (EAT) Upgraded; (RIMM) (GG) (HLF) Downgraded
Oct 18, 2012 10:19AM Needham & Company Raises Aegerion Pharmaceuticals (AEGR) Price Target to $30
Oct 12, 2012 01:29PM Unusual 11 Mid-Day Movers 10/12: (NINE) (GLUU) (NPSP) Higher; (AEZS) (OCZ) (TZOO) Lower
Jun 25, 2012 07:43AM Needham & Company Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Profitability By 2014
May 22, 2012 07:19AM Needham & Company Starts Aegerion Pharmaceuticals (AEGR) at Buy; Looking For Approval of Oral Orphan Cardiac Disease Treatment
May 31, 2011 11:18AM Needham & Company Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); When More of the Same is a Good Thing – 56-Wk Follow-up Data Consistent
Mar 3, 2011 07:45AM Needham & Company Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Now (Enhanced Mgmt Team, Robust Phase 3 Primary Endpoint Data) and Then (Phase 3 56-week follow-up 2Q11, FDA submission likely
Jan 5, 2011 07:52AM Needham & Company Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Robust Efficacy and Manageable Safety of Lomitapide in HoFH Bode Well for Regulatory Submission in 2H11;
Dec 2, 2010 07:28AM Needham & Company Starts Aegerion Pharmaceuticals (AEGR) at Buy; Time to Light the Candles, as Lomitapide May Provide a Bright Festival